About Us
Coming together to provide unwavering support for one another
Our Mission
To ensure every family facing multiple myeloma in China has access to clear, evidence-based medical information and a supportive community of peers—regardless of geography, income, or medical literacy.
Our Vision
A future where no myeloma patient in China fights alone—where every patient can access world-class treatment information, navigate the healthcare system with confidence, and draw strength from a network of fellow warriors.
A Message from the Founder
Our original vision for CMDN was simple: in an era of information overload and medical resource barriers, we want to ensure every family facing multiple myeloma can find a clear path forward.
We deeply understand the overwhelming sense of isolation when staring at dense lab reports, deciphering obscure medical jargon, and facing uncertain treatment options. Therefore, we are dedicated to bridging the information gap by organizing clear, authoritative clinical guidelines, practical health insurance policies, and access to cutting-edge treatments for you. We hope that by providing accessible information, we can eliminate the fear born of the unknown and make scientifically sound treatment decisions within reach.
But what matters even more than information is the human connection. Here, you are no longer fighting alone. To date, we have united over two thousand fellow myeloma warriors. Within this extended family, authentic medical experiences and mutual, uplifting warmth are shared every single day. There is no clinical detachment here—only fellow travelers answering your questions and supporting one another. For every resilient patient and family, we stand ready to walk this journey with you.
— Andy Chen, Founder of CMDN
Our Impact
2000+
Fellow Cancer Fighters
50+
Authoritative Guidelines
71+
Clinical Trial Records
Our Team
Andy Chen
Founder & Director
Enterprise architect turned AI entrepreneur and patient advocate. Andy founded CMDN after his father was diagnosed with multiple myeloma, combining his deep technical expertise with a deeply personal mission. He also serves as Founder & CEO of CastMaster, the digital transformation company powering CMDN's technology platform.
Powered by Technology
CastMaster
Invisible AI. Visible Impact.
CMDN's entire digital infrastructure is built and maintained by CastMaster — a digital company empowering AI transformation across various industries. CastMaster excels at cross-disciplinary innovation, turning the impossible into reality. Their invisible engine enables a team of just 3 people to serve 2,000+ patients at scale.
What We Can Do for You
Three core service pillars addressing the most urgent informational needs of myeloma families along their treatment journey
Authoritative Guideline Interpretation
Aggregating the latest myeloma clinical guidelines from top-tier institutions like NCCN, CSCO, and IMWG. We provide translated guides and tagged retrieval systems, making complex medical literature transparent and accessible.
Browse Guidelines →CAR-T in China Information
Independent evidence, hospital tiers, pricing transparency, and anti-scam facts for international patients.
Explore CAR-T in China →International Patient Advocacy
CMDN's navigation support is free. We help patients compare written hospital information, avoid unnecessary intermediary markups and seek transparent, patient-favorable terms where possible.
Review the Patient Process →Our Unwavering Principles
These three principles form the absolute baseline for every decision we make
Scientific Rigor
All content relies strictly on authoritative institutional sources. We refuse to propagate unverified remedies or exaggerated claims, maintaining a meticulously responsible approach to every piece of medical information.
Patients First
We reject any commercial partnerships that might compromise our editorial integrity. We stand firmly alongside patients and their families. Your right to objective information supersedes all commercial interests.
Peer Solidarity
Here, there is no divide between experts and patients—only an authentic exchange of lived experiences among peers. Every patient who shares their journey is a foundational architect of this community.
You Are Also a Fellow Traveler on This Journey
Whether you are a patient, a family member, or a medical professional dedicated to the myeloma field, you have a place here. Join us, and walk alongside over two thousand resilient individuals.
Frequently Asked Questions About CMDN
Independent facts regarding our nonprofit status, funding, and clinical navigation
- Q1Is CMDN a hospital or medical clinic?
- No. CMDN is a nonprofit patient-founded advocacy network and research registry. We are not a medical clinic, hospital, or commercial healthcare provider, and we do not provide direct medical treatment or individual prescriptions.
- Q2Does CMDN charge fees for consultations or trial matching?
- All services provided to patients and families are 100% free of charge. CMDN never charges consultation fees, membership dues, referral commissions, or finder fees for clinical trial access.
- Q3Is CMDN a commercial broker or pharmaceutical agent?
- No. CMDN does not sell medications, medical devices, or supplements, and we strictly prohibit accepting patient-referral kickbacks from pharmaceutical manufacturers or private brokers. All information is maintained with strict editorial independence.
- Q4What are the sources of CMDN clinical trials and medical content?
- Clinical trial records are derived directly from the official drug clinical trial registry of the National Medical Products Administration (NMPA CDE). Medical educational guidelines align with published consensus from CSCO, NCCN, and the International Myeloma Working Group (IMWG).
- Q5How does CMDN assist myeloma patients and families?
- CMDN provides three core services: 1. A neutral clinical trial directory spanning nationwide research centers in China; 2. Accessible, evidence-based educational topics and health insurance coverage guides; 3. The "Myeloma Companion" (care.chinamyeloma.org) digital tracking tool for longitudinal lab monitoring.
Disclaimer: All content on this platform (including guideline summaries, hospital and pricing facts, clinical trial records, hospital information and patient narratives) is strictly for reference and does not constitute medical advice, diagnosis, a treatment recommendation or a guarantee of acceptance or outcome. Please consult qualified clinical teams for individual decisions.